Page last updated: 2024-08-24

gemcitabine and maytansine

gemcitabine has been researched along with maytansine in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hayashi, K; Homma, S; Ishidao, T; Ito, M; Kamata, Y; Kan, S; Koido, S; Komita, H; Nagasaki, E; Okamoto, M	1
Hayashi, K; Homma, S; Ito, M; Kamata, Y; Kan, S; Koido, S; Komita, H; Nagasaki, E; Okamoto, M	1

Trials

1 trial(s) available for gemcitabine and maytansine

Article	Year
Highlights of the NCCN Oncology Research Program. Journal of the National Comprehensive Cancer Network : JNCCN, 2019, Volume: 17, Issue:1 Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Female; Folate Receptor 1; Gemcitabine; Humans; Immunoconjugates; Male; Maytansine; Neoplasm Recurrence, Local; Neoplasms; Progression-Free Survival; Young Adult	2019

Article

Year

Highlights of the NCCN Oncology Research Program.

Journal of the National Comprehensive Cancer Network : JNCCN, 2019, Volume: 17, Issue:1

Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Female; Folate Receptor 1; Gemcitabine; Humans; Immunoconjugates; Male; Maytansine; Neoplasm Recurrence, Local; Neoplasms; Progression-Free Survival; Young Adult

2019

Other Studies

2 other study(ies) available for gemcitabine and maytansine

Article	Year
Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. Oncology reports, 2015, Volume: 34, Issue:1 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Maytansine; MCF-7 Cells; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Up-Regulation	2015
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. BMC cancer, 2015, Oct-16, Volume: 15 Topics: Adenocarcinoma; Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Maytansine; Mice; Pancreatic Neoplasms; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays	2015

Article

Year

Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine.

Oncology reports, 2015, Volume: 34, Issue:1

Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Maytansine; MCF-7 Cells; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Up-Regulation

2015

Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells.

BMC cancer, 2015, Oct-16, Volume: 15

Topics: Adenocarcinoma; Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Maytansine; Mice; Pancreatic Neoplasms; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays

2015